COMP <GO>
LXEO vs OCGN // 10Y YIELD & FRED MACRO BETA
Lexeo Therapeutics Inc. (NASDAQ) VS. Ocugen Inc. (NASDAQ) • 15-METRIC TALLY: LXEO 1
— OCGN 2
■ METRIC PARITY
LAST: $3.14 (+2.61%) • MKT CAP: $251.1M
macro-sensitivity
—
LAST: $0.70 (-5.58%) • MKT CAP: $252.4M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LXEO VS. OCGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LXEO | OCGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -22.65% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 8.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | OCGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.1 | 34.7 | +11.40 | LXEO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $251.1M | $252.4M | -$1.3M | OCGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LXEO REV | OCGN REV | LXEO GROSS % | OCGN GROSS % | LXEO FCF | OCGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $4.4M | — | — | -$99.0M | -$57.1M |
| FY 2024 | $0 | $4.1M | — | — | -$81.6M | -$45.5M |
| FY 2023 | $0 | $6.0M | — | — | -$59.5M | -$62.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LXEO // BETA —
OCGN // BETA —